Comparison · NCT02388724-sae
Vonoprazan 20 mg vs Lansoprazole 30 mg: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Vonoprazan 20 mg vs Lansoprazole 30 mg: serious adverse events. Trial comparisons, record NCT02388724-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02388724-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0123 | 0.00419 | 0.0355 | wilson | |
| Risk in group 2 | 0.0128 | 0.00435 | 0.0369 | wilson | |
| Risk difference, group 1 minus group 2 | -0.000471 | -0.0259 | 0.0242 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.963 | 0.196 | 4.72 | log | |
| Odds ratio, group 1 over group 2 | 0.963 | 0.192 | 4.82 | log | |
| Number needed to treat, for one fewer participant with a serious adverse event on Vonoprazan 20 mg than on Lansoprazole 30 mg | 2,120 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Vonoprazan 20 mg | Vonoprazan 20 mg, tablet, orally, once daily and lansoprazole placebo-matching capsule, orally, once daily for up to 8 weeks. | 3 | 244 | EG000 |
| Group 2 | Lansoprazole 30 mg | Lansoprazole 30 mg, capsule, orally, once daily and vonoprazan placebo-matching tablet, orally, once daily for up to 8 weeks. | 3 | 235 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- Up to 10 weeks (8 weeks of treatment and 2 weeks of post-treatment follow-up period)
Source ClinicalTrials.gov
Trial
- Title
- Efficacy and Safety of Oral Once-Daily Vonoprazan (TAK-438) in Participants With Erosive Esophagitis
- NCT number
- NCT02388724
- Phases
- PHASE3
- Conditions
- Erosive Esophagitis
- Interventions
- Vonoprazan, Lansoprazole, Vonoprazan Placebo, Lansoprazole Placebo
- Lead sponsor
- Takeda
- Results first posted
- 2019-06-03
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02388724?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02388724-sae